Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing Symptoms of Allergic Rhinitis: Randomized, Double-blind, Placebo-controlled Trial
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 95
- Locations
- 21
- Primary Endpoint
- percentage of patients with a change of at least 23 mm VAS (Visual Analogue Scale) at D4
Study Overview
Brief Summary
A nasal spray based on Advanced Water S-100 ionized water would clean the nasal cavities, reduce the viscosity of mucus and facilitate its elimination and decongestion of the nose and the prevention of the bridging of the allergen to the epithelial cells of the cavity nose at the origin of the onset of symptoms.
Indeed, a water-based nasal spray ionized Advanced Water S-100 would modify the electrostatic environment of all the interactions ensuring this bridging. Negative ions (OH-) contained in water ionized Advanced Water S-100 competes with negative ions from acids negatively charged amino acids and also neutralize basic amino acids positively charged. The destabilization of all the links governing the process of epitope/IgE association would prevent the bridging of the FcɛRI receptors of the mast cell and thus the cascade of cellular responses that cause symptoms.
The purpose of this study is to assess whether the use of ionized water nasal spray ADW S-100 allows to sufficiently reduce the intensity of the symptoms of allergic rhinitis and thus improve the quality of life of people with allergies.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men and women ≥ 18 years old
- •Inform consent
- •Beneficiaries of a social security scheme
- •Having documented persistent or intermittent allergic rhinitis for at least 2 years
- •In the respiratory environment allergen battery, at least one prick-test positive at selection (diameter >3mm compared to the negative control), or prick-test or specific IgE assay less than 6 months old demonstrating an allergic response appropriate
- •Agreeing not to take anti-allergic drug treatment during the duration of the study except in case of aggravation of the disease
- •Having a smartphone or a computer allowing access to the application of seizure
- •To be eligible to be randomized, participants must have:
- •Used the nasal spray at least 2 times a day during the run-in, according to their answers on the application
- •A median VAS for the evaluation of the discomfort due to the symptoms of the selection at D-1 ≥ 50mm
- •Non-inclusion Criteria:
- •Existence of links with any member of the study staff or the sponsor, or conflicts interests with the promoter
- •Known hypersensitivity or allergy to one of the components of the product tested
- •Contraindication to the use of a nasal spray
- •Respiratory pathology other than allergic rhinitis/rhino-conjunctivitis and asthma mild or moderate. People with severe asthma may be included if their asthma is controlled
- •Current treatment with systemic corticosteroids
- •Known pregnancy or positive urine pregnancy test at screening and/or at D0, or breastfeeding in progress
- •Participation in a clinical trial or other clinical investigation using a device medicine for the treatment or prevention of rhinitis or conjunctivitis
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
percentage of patients with a change of at least 23 mm VAS (Visual Analogue Scale) at D4
Time Frame: 14 days
minimum 0 and maximum 100 (higher scores mean a worse outcome)
Secondary Outcomes
- percentage of change on D4 and D14 compared to D0 of symptoms (nasal obstruction, sneezing, rhinorrhea, sore throat)(14 days)
- percentage of change on D4 and D14 compared to D0 of eye symptoms (itching, tearing, redness)(14 days)
- percentage of patients without symptoms at D4 and D14(14 days)
- percentage of patients who used antihistamines(14 days)
- Proportion of premature discontinuations of the study or discontinuations of the product under study(14 days)
- Proportion of attendees presenting events adverse events (AE), serious adverse events (SUE), AEs related to the product of the study, AEs of interest particular: respiratory infections(14 days)
- VAS from D0 to D14(14 days)
- Allergic rhinitis control test on D0 and D14(14 days)
- Proportion of participants - satisfied or very satisfied - judging the use easy or very easy(14 days)